Pfizer quarterly results and financials

Pfizer (PFIZER)₹3,918+0.36%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (standalone), Pfizer reported sales of ₹653 Cr, up 8.2% from Jun 2025, and net profit of ₹204 Cr, up 6.4% year on year. For the year to Mar 2026, sales were ₹2,522 Cr and net profit ₹722 Cr.

Sales (Jun 2026): ₹653 Cr
Net profit (Jun 2026): ₹204 Cr
Sales (FY Mar 2026): ₹2,522 Cr
Net profit (FY Mar 2026): ₹722 Cr
EPS (Jun 2026): ₹44.59
Borrowings (Mar 2026): ₹70.07 Cr

Company filings, standalone accounts; latest reported quarter Jun 2026

Pfizer quarterly results

₹ crore unless stated; each column is a quarter.

Pfizer Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	575	540	547	564	589	538	592	603	642	645	630	653
Expenses	392	386	356	384	398	391	363	392	411	416	392	405
Operating Profit	183	153	189	177	189	146	229	210	230	229	236	248
OPM %	31.9%	27.9%	34.9%	31.9%	31.9%	26.9%	37.9%	34.9%	35.9%	34.9%	37.9%	37.9%
Other Income	35.89	43.84	74.72	41.86	42.84	42.86	216	66.77	41.85	−19.93	49.84	44.86
Interest	3.01	3.01	7.01	2.01	2.01	2.01	3.01	3.01	2.01	2.01	2.01	1.01
Depreciation	14.99	17.98	13.99	14.99	14.99	14.99	15.98	13.99	13.99	13.99	14.99	13.99
Profit before tax	201	176	244	203	215	172	425	260	255	192	269	277
Tax %	25.9%	25.9%	27.0%	26.0%	25.9%	26.0%	22.0%	26.0%	26.0%	25.9%	26.0%	25.9%
Exceptional items	0.00	5.98	0.00	0.00	0.00	0.00	133	0.00	0.00	−40.89	6.98	0.00
Net Profit	149	130	179	151	158	128	331	192	189	142	200	204
EPS (Rs)	32.49	28.34	39.02	32.87	34.55	27.83	72.14	41.82	41.24	30.91	43.59	44.59

Pfizer profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Pfizer Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	2,012	1,965	1,971	2,084	2,153	2,238	2,612	2,423	2,193	2,281	2,522	2,569
Expenses	1,576	1,614	1,465	1,514	1,574	1,522	1,771	1,612	1,551	1,536	1,611	1,624
Operating Profit	434	351	502	567	576	713	837	810	639	744	905	944
OPM %	21.9%	17.9%	24.9%	26.9%	26.9%	31.9%	31.9%	32.9%	28.9%	32.9%	35.9%	36.7%
Other Income	96.74	231	114	167	182	80.73	62.75	134	184	343	139	117
Interest	1.01	2.01	1.01	2.01	11.02	15.02	11.03	13.03	15.02	8.01	10.03	7.04
Depreciation	57.99	62.91	65.93	70.99	103	109	115	106	61.99	60.93	57.96	56.96
Profit before tax	470	517	548	660	641	668	773	823	745	1,014	974	992
Tax %	34.9%	34.9%	34.0%	34.9%	21.0%	25.9%	20.9%	23.9%	26.0%	24.0%	26.0%	—
Exceptional items	5.98	82.82	0.00	0.00	−0.99	0.00	0.99	22.96	3.99	215	−35.89	−33.91
Net Profit	305	337	360	429	510	499	614	624	551	768	722	735
EPS (Rs)	66.49	73.43	78.47	93.60	110.95	108.55	133.66	136.11	120.27	167.33	157.58	160.33
Dividend payout %	22.0%	27.0%	25.0%	24.0%	297.0%	32.0%	26.0%	29.0%	29.0%	98.0%	48.0%	—

Pfizer balance sheet

₹ crore, at each year end.

Pfizer Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	46.10	46.10	46.10	46.06	46.06	46.06	46.05	46.07	46.09	46.04	46.07	46.07
Reserves	1,924	2,115	2,370	2,632	2,961	3,346	2,342	2,813	3,158	3,548	4,169	4,154
Borrowings	1.99	2.01	1.99	2.01	1.99	2.01	62.97	39.03	41.00	40.04	108	70.07
Other Liabilities	641	725	844	1,009	930	1,012	814	1,002	756	596	588	652
Total Liabilities	2,614	2,889	3,262	3,690	3,940	4,406	3,265	3,900	4,001	4,229	4,911	4,922
Fixed Assets	946	927	904	952	889	975	896	871	751	715	726	680
CWIP	13.03	3.01	15.04	1.01	0.00	1.01	3.01	1.01	8.02	0.00	8.01	20.04
Investments	42.97	36.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	1,612	1,921	2,342	2,736	3,051	3,430	2,366	3,027	3,242	3,515	4,178	4,222
Inventories	387	360	321	296	386	430	434	448	417	433	475	472
Trade receivables	160	142	110	155	172	172	109	143	152	188	193	182
Cash & equivalents	610	1,027	1,525	1,773	1,918	2,225	1,117	1,645	1,863	2,049	2,807	3,115
Total Assets	2,614	2,889	3,262	3,690	3,940	4,406	3,265	3,900	4,001	4,229	4,911	4,922

Pfizer cash flow

₹ crore, for each year.

Pfizer Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	113	346	330	333	98.42	324	429	670	357	258	662	971
Cash from investing activity	68.08	−701	−250	−238	34.99	1,532	−469	−575	−36.01	53.98	−71.04	−562
Cash from financing activity	−0.99	−62.01	−82.96	−110	−110	−164	−1,570	−181	−346	−235	−205	−798
Net cash flow	181	−417	−2.99	−16.99	22.99	1,687	−1,610	−87.93	−25.95	74.95	382	−392
Capex	20.93	43.85	24.92	103	3.99	16.94	17.95	14.94	64.79	18.95	27.92	24.90
Free cash flow	93.35	399	396	263	125	344	412	656	293	292	786	947
CFO / OP %	62.0%	120.0%	146.0%	105.0%	59.0%	93.0%	89.0%	107.0%	81.0%	64.0%	110.0%	105.0%

Pfizer ratios

Working-capital days and returns, by year.

Pfizer Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	32	26	20	29	30	29	18	20	23	31	31	26
Inventory days	192	168	149	148	190	199	200	174	176	201	215	196
Days payable	165	157	178	245	213	197	130	102	91	77	68	89
Cash conversion cycle	58	36	−10	−69	6	31	87	91	107	154	177	132
Working capital days	6	−10	−48	−58	−17	−9	2	−15	0	23	22	8
ROCE %	24.0%	22.0%	17.0%	21.0%	23.0%	20.0%	23.0%	29.0%	26.0%	22.0%	21.0%	24.0%

Pfizer: frequently asked questions

What are the latest quarterly results of Pfizer?

For the Jun 2026 quarter, Pfizer reported sales of ₹653 Cr, up 8.2% year on year and net profit of ₹204 Cr, up 6.4% year on year. The operating margin was 37.9%.

What is the annual revenue of Pfizer?

Pfizer's sales for the year to Mar 2026 were ₹2,522 Cr; over the last twelve months they were ₹2,569 Cr.

What is the net profit of Pfizer?

Net profit for the year to Mar 2026 was ₹722 Cr, and ₹735 Cr over the last twelve months. Earnings per share over the same trailing period were ₹160.33.

How much debt does Pfizer have?

Pfizer reported borrowings of ₹70.07 Cr at Mar 2026, against cash and equivalents of ₹3,115 Cr.

What is the free cash flow of Pfizer?

Cash from operations was ₹971 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹947 Cr.

Loading…